Kim Cantor, Lupus Foundation of America’s Senior Director of Public Policy and Government Relations, discusses the Foundation’s Medicare for Patients RX (MAPRx) Coalition
News & Stories
Lupus Foundation of America medical director Dr. Joan Merrill discusses a recently completed a study that may help to improve the design for future lupus clinical trials and secure approval of new safe and more tolerable treatments for lupus.
In her Expert Column, Dr. Joan T. Merrill, Medical Director, explains why antimalarial medicines are now used to treat lupus.
Ask the Expert: Dr. Betsy Blazek O'Neill discusses complementary medicines and lupus
According to research presented this week at the American College of Rheumatology Annual Meeting, researchers have identified three potentially modifiable risk factors and one protective medication that may improve the health of people living with lupus.
Researchers from the University of California and Brigham and Women’s Hospital in Boston recently examined adherence among Medicaid beneficiaries with lupus to prescribed medications and found the patients were not following treatment plans, putting themselves at risk for poor outcomes.
The Health Insurance Marketplace offers coverage to many Americans who currently do not have health insurance. We have gathered relevant links to help you locate the information you need to know.
New study reinforces need for Patients’ Access to Treatments Act (H.R. 460) to reduce excessive financial burden placed on people with chronic diseases
People with lupus who were treated with hydroxychloroquine (HCQ), an anti-malarial drug, early after a diagnosis of lupus had less cumulative organ damage at three years after diagnosis than those who did not receive HCQ, according to a new analysis.
After more than a half-century of drought, many new treatments are in development for lupus. However, approval of a new treatment does not ensure that all people with lupus will be able to try it.
A new study sheds light on the specific effects of drug treatments versus disease activity as risk factors for lymphoma, a type of cancer, among people with lupus.
Our national lupus research program aggressively seeks to advance the science and medicine of lupus and to improve the quality of life for all people affected by lupus.
The results of this study indicate that current use of steroids (20 mg/day or more) is perhaps the most significant risk factor for heart disease in individuals with lupus.
The Lupus Foundation of America is calling on the Department of Health and Human Services to ensure that people with chronic diseases get access to medications.
Dr. Murray Urowitz discusses current and potential new therapies for managing lupus.
Rontalizumab is a potential new drug to treat lupus. It reduces the effects of the excessive interferon-alpha that is so characteristic of lupus. The researchers hoped to learn about the safety and tolerability of rontalizumab in people with mild lupus disease activity.
People with lupus are at increased risk of cardiovascular disease, especially when taking steroids. The use of anti-malarial drugs, such as hydroxychloroquine, significantly reduces this risk.
This study examined the long-term safety of belimumab over a 4-year period in people with lupus. The results highlight the long-term safety of belimumab over a 4-year period.
If your luggage is exposed to extreme temperatures or humidity, your medications could lose potency and effectiveness.
Dr. Richard Furie of the North Shore-Long Island Jewish Health System provides an overview of how lupus is treated.
Lupus Foundation of America Medical Director Dr. Joan Merrill provides an overview of lupus and its health effects.
The findings highlight specific kinds of changes in lupus biomarkers that are most associated with effective use of belimumab in the treatment of lupus.
The researchers hoped to learn about the safety and efficacy of atorvastatin (Lipitor®) in reducing cholesterol in children with lupus.
The New England Journal of Medicine published results from a long-term study for the treatment of lupus nephritis.
Dr. Emily von Scheven of the University of California at San Francisco discusses the development of consensus treatment plans for proliferative nephritis in juvenile systemic lupus.
Dr. Michelle Petri of the Johns Hopkins University Medical Center discussed the results of a study of vitamin D supplementation in people with lupus.
National lupus organizations, and individuals with lupus and their families around the world, are rallying to protect access to new treatments of lupus.
Health Canada and European Regulators have approved BENLYSTA™.
Don’t make your lupus worse by ignoring your doctor’s instructions—take your medications as prescribed. And if there is some reason you aren’t taking them, talk to your doctor or pharmacist. Help them to help you!
The approval of Benlysta—the first lupus drug in more than 50 years—ushers in a new era of treatment.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion, recommending marketing authorisation for BENLYSTA®.
The U.S. Food and Drug Administration (FDA) approved the drug, BENLYSTA®, for the treatment of lupus, an autoimmune disease.
Human Genome Sciences and GlaxoSmithKline announced publication of the BLISS-52 study of BENLYSTA®.
Epratuzumab is an investigational agent for the treatment of lupus. The researchers hoped to learn whether epratuzumab could be a safe and effective treatment for people with moderate-to-severe lupus.
There are a number of treatments used for lupus nephritis, but none of them are approved by the U.S. Food and Drug Administration (FDA). The researchers hoped to compare the efficacy and safety of MMF and azathioprine as maintenance therapy.
The researchers hoped to learn whether treatment with belimumab could reduce the use of steroids in people with active lupus.
The researchers hoped to learn whether there are any tests that could predict low blood sugar in women with lupus taking hydroxychloroquine.
Keeping track of your medications, and taking them correctly, can feel overwhelming. Learn more about how to get the most out of your medications.
Dr. Isenberg discusses several of the new agents under evaluation for lupus and looks to ways lupus treatment will change with evolving technology and new scientific findings.
The researchers hoped to learn what factors have an impact on how much time it takes for a lupus patient to develop skin damage.
The researchers hoped to determine the risk of developing blood clots in people with lupus, while factoring in the year of diagnosis and disease severity.
The researchers wanted to compare the effectiveness of mycophenolate mofetil (CellCept) with that of azathioprine to prevent kidney flares after the initial treatment for nephritis was successful.
The researchers hoped to learn about the safety and potential effectiveness of belimumab in the treatment of lupus.
Hydroxychloroquine belongs to the family of medicines called “antimalarials” (AMs), which are also classified as disease-modifying anti-rheumatic drugs, or DMARDs. These drugs were initially used to prevent and to treat malaria but are no longer used for those purposes.
Dr. David Wofsy of the University of California, San Francisco, leads a discussion and takes questions about being newly diagnosed and living with lupus.
This trial was the first stage of testing for rontalizumab, which is a new treatment that interferes with an inflammatory protein called "interferon-alpha."
Our Annual Lupus Symposium in Augusta has moved to March 22, 2014!
Questions about coping with Lupus? Sign up today!